2. Academic Validation
  3. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors

Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors

  • Eur J Med Chem. 2014 Mar 3;74:574-605. doi: 10.1016/j.ejmech.2013.12.038.
Bhumika D Patel 1,  Manjunath D Ghate 2
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad 382481, Gujarat, India. Electronic address: [email protected].
  • 2 Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad 382481, Gujarat, India.
PMID: 24531198 DOI: 10.1016/j.ejmech.2013.12.038
Abstract

Dipeptidyl peptidase-4 (DPP-4) is one of the widely explored novel targets for Type 2 diabetes mellitus (T2DM) currently. Research has been focused on the strategy to preserve the endogenous glucagon like peptide (GLP)-1 activity by inhibiting the DPP-4 action. The DPP-4 inhibitors are weight neutral, well tolerated and give better glycaemic control over a longer duration of time compared to existing conventional therapies. The journey of DPP-4 inhibitors in the market started from the launch of sitagliptin in 2006 to latest drug teneligliptin in 2012. This review is mainly focusing on the recent medicinal aspects and advancements in the designing of DPP-4 inhibitors with the therapeutic potential of DPP-4 as a target to convey more clarity in the diffused data.

Keywords

Diabetes; Dipeptidyl peptidase-4; Glucagon like peptide (GLP)-1; Non-peptidomimetics; Peptidomimetics.

Figures
Products